CD33

CD33 (Siglec-3) operates in direct opposition to TREM2, functioning as a primary inhibitory receptor on the microglial surface. As an ITIM-containing (Immunoreceptor Tyrosine-based Inhibitory Motif) sialic acid-binding receptor, its physiological role is to "brake" microglial activation to prevent runaway inflammation.

In Alzheimer's pathology, however, excessive CD33 signaling puts a pathological halt on the microglial ability to clear amyloid-beta. GWAS studies identified that higher CD33 expression correlates with significantly elevated amyloid burden and cognitive decline. The signaling axis recruits the phosphatases SHP-1 and SHP-2, which aggressively shut down the pro-phagocytic SYK signaling cascade—essentially "turning off" the cell's ability to transition into a protective state.

Fascinatingly, a protective genetic variant acts as a natural CD33 inhibitor: the rs3865444 minor allele heavily favors the production of a truncated CD33 isoform (D2-CD33) that lacks the sialic acid-binding domain. Individuals with this protective variant have more phagocytically active microglia, confirming CD33 as a prime target for antagonistic antibodies (like AL003) to lift the brake off the microglial immune system.